Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 34
1978 207
1979 292
1980 492
1981 485
1982 508
1983 590
1984 561
1985 611
1986 578
1987 518
1988 537
1989 530
1990 477
1991 455
1992 429
1993 364
1994 334
1995 331
1996 340
1997 295
1998 204
1999 272
2000 243
2001 261
2002 228
2003 251
2004 265
2005 244
2006 258
2007 246
2008 221
2009 191
2010 208
2011 165
2012 219
2013 215
2014 151
2015 164
2016 158
2017 172
2018 158
2019 140
2020 153
2021 130
2022 105
2023 94
2024 29

Text availability

Article attribute

Article type

Publication date

Search Results

13,656 results

Results by year

Filters applied: . Clear all
Page 1
Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.
Nathan SD, Waxman A, Rajagopal S, Case A, Johri S, DuBrock H, De La Zerda DJ, Sahay S, King C, Melendres-Groves L, Smith P, Shen E, Edwards LD, Nelsen A, Tapson VF. Nathan SD, et al. Lancet Respir Med. 2021 Nov;9(11):1266-1274. doi: 10.1016/S2213-2600(21)00165-X. Epub 2021 Jun 29. Lancet Respir Med. 2021. PMID: 34214475 Clinical Trial.
Prostacyclin.
Vane JR. Vane JR. J R Soc Med. 1983 Apr;76(4):245-9. doi: 10.1177/014107688307600401. J R Soc Med. 1983. PMID: 6341583 Free PMC article. No abstract available.
Prostacyclin-analogs.
Nickolson RC, Town MH, Vorbrüggen H. Nickolson RC, et al. Med Res Rev. 1985 Jan-Mar;5(1):1-53. doi: 10.1002/med.2610050102. Med Res Rev. 1985. PMID: 3884930 Review. No abstract available.
Epoprostenol for the treatment of pulmonary arterial hypertension.
Cristo Ropero MJ, Cruz-Utrilla A, Escribano-Subias MP. Cristo Ropero MJ, et al. Expert Rev Clin Pharmacol. 2021 Aug;14(8):1005-1013. doi: 10.1080/17512433.2021.1929925. Epub 2021 Jun 7. Expert Rev Clin Pharmacol. 2021. PMID: 34030557 Review.
Since the first demonstration of survival benefit of intravenous epoprostenol in monotherapy in 1996, prostanoids remain the cornerstone for PAH patients at high risk. ...A deep literature search was carried out on the MEDLINE database for published literature before March …
Since the first demonstration of survival benefit of intravenous epoprostenol in monotherapy in 1996, prostanoids remain the cornerst …
Prostaglandin I2 (prostacyclin).
Kelton JG, Blajchman MA. Kelton JG, et al. Can Med Assoc J. 1980 Jan 26;122(2):175-9. Can Med Assoc J. 1980. PMID: 6988063 Free PMC article. Review.
Epoprostenol Therapy for Pulmonary Arterial Hypertension.
Akagi S, Nakamura K, Matsubara H, Ogawa A, Sarashina T, Ejiri K, Ito H. Akagi S, et al. Acta Med Okayama. 2015;69(3):129-36. doi: 10.18926/AMO/53519. Acta Med Okayama. 2015. PMID: 26101188 Free article. Review.
Pulmonary arterial hypertension (PAH) is characterized by elevation of pulmonary artery pressure caused by pulmonary vasoconstriction and vascular remodeling, which leads to right heart failure and death. Epoprostenol (prostaglandin I2) has a potent short-acting vasodilato …
Pulmonary arterial hypertension (PAH) is characterized by elevation of pulmonary artery pressure caused by pulmonary vasoconstriction and va …
Epoprostenol sodium for treatment of pulmonary arterial hypertension.
Saito Y, Nakamura K, Akagi S, Sarashina T, Ejiri K, Miura A, Ogawa A, Matsubara H, Ito H. Saito Y, et al. Vasc Health Risk Manag. 2015 May 14;11:265-70. doi: 10.2147/VHRM.S50368. eCollection 2015. Vasc Health Risk Manag. 2015. PMID: 25999730 Free PMC article. Review.
Here, we provide an overview of the current clinical data for epoprostenol. Epoprostenol treatment improves symptoms, exercise capacity, and hemodynamics, and is the only treatment that has been shown to reduce mortality in patients with idiopathic PAH (IPAH) in ran …
Here, we provide an overview of the current clinical data for epoprostenol. Epoprostenol treatment improves symptoms, exercise …
Prostacyclins in Cardiac Surgery: Coming of Age.
Deshpande SP, Mazzeffi MA, Strauss E, Hollis A, Tanaka KA. Deshpande SP, et al. Semin Cardiothorac Vasc Anesth. 2018 Sep;22(3):306-323. doi: 10.1177/1089253217749298. Epub 2017 Dec 25. Semin Cardiothorac Vasc Anesth. 2018. PMID: 29277148 Review.
Evidence for the Use of Epoprostenol to Treat Raynaud's Phenomenon With or Without Digital Ulcers.
Cruz JE, Ward A, Anthony S, Chang S, Bae HB, Hermes-DeSantis ER. Cruz JE, et al. Ann Pharmacother. 2016 Dec;50(12):1060-1067. doi: 10.1177/1060028016660324. Epub 2016 Jul 26. Ann Pharmacother. 2016. PMID: 27465880 Review.
OBJECTIVE: To review the evidence for using intravenous (IV) epoprostenol to treat Raynaud's phenomenon (RP). DATA SOURCES: The databases MEDLINE (1946 to March 2016), PubMed, and International Pharmaceutical Abstracts were searched using the terms epoprostenol, Flo …
OBJECTIVE: To review the evidence for using intravenous (IV) epoprostenol to treat Raynaud's phenomenon (RP). DATA SOURCES: The datab …
Prostacyclin and atherosclerosis.
Wagner BM. Wagner BM. Hum Pathol. 1985 Mar;16(3):201. doi: 10.1016/s0046-8177(85)80001-0. Hum Pathol. 1985. PMID: 3882549 No abstract available.
13,656 results
You have reached the last available page of results. Please see the User Guide for more information.